Dare Bioscience (NASDAQ:DARE – Get Free Report) issued its quarterly earnings data on Monday. The biotechnology company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05), Zacks reports. Dare Bioscience had a negative return on equity of 748.30% and a negative net margin of 803.80%.
Dare Bioscience Stock Down 11.1%
DARE traded down $0.07 during trading hours on Monday, hitting $0.58. 184,649 shares of the company’s stock were exchanged, compared to its average volume of 374,677. The stock has a market cap of $11.49 million, a price-to-earnings ratio of -0.83 and a beta of 1.11. Dare Bioscience has a 1-year low of $0.58 and a 1-year high of $3.78. The stock’s 50-day moving average is $0.73 and its two-hundred day moving average is $1.51.
Analyst Ratings Changes
DARE has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. Weiss Ratings lowered Dare Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. UBS Group set a $1.00 price target on Dare Bioscience in a report on Monday, September 14th. Ladenburg Thalmann & Co. Inc. began coverage on Dare Bioscience in a research report on Monday, October 26th. They set a “buy” rating and a $2.00 price objective for the company. Finally, Benchmark reiterated a “buy” rating on shares of Dare Bioscience in a report on Monday, August 17th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.
About Dare Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company focused on developing therapies and products for women’s health. Its work spans areas including contraception, vaginal health and sexual health, with an emphasis on addressing conditions and needs that have had limited treatment options. The company’s product candidates include Ovaprene, a hormone-free, monthly-use vaginal contraceptive, and investigational treatments for conditions such as female sexual arousal disorder. These candidates remain in development and are not approved for general use.
Featured Stories
- Five stocks we like better than Dare Bioscience
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Dare Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
